- Business
- Humanwell Healthcare (Group) Co., Ltd. (600079.SS) researches, develops, produces and sells pharmaceutical products principally in China and internationally, with a focus on anesthetics, fertility-regulating drugs, steroid hormones, central nervous system medications, Uyghur ethnic medicines, skin topical drugs, respiratory system drugs, anti-infection drugs, traditional Chinese medicines, medical devices, over-the-counter medicines, herbal medicines and biological products; specific offerings include sufentanil citrate injection, remifentanil hydrochloride for injection, hydromorphone hydrochloride injection, nalbuphine hydrochloride injection, alfentanil hydrochloride injection, remimazolam besylate injection, mifepristone preparations, zuka wood particles, compound muniziqi granules, urokinase for injection, neomycin sulfate API preparations, progesterone API preparations, remazolam besylate for injection (RuiMa), fospropofol disodium for injection (LinBingFen) and snowbellleaf tickclover general flavone capsule (Guang Shi Tong). The company, founded in 1993 and headquartered in Wuhan, China, operates subsidiaries and facilities including EPIC Pharma and St. Louis R&D Center in the US, PuraCap Pharmaceuticals in New Jersey and Wuhan, YiChang Humanwell Pharmaceutical, Likang Pharmaceutical, Paion Pharma in Germany, Humanwell Pharma Mali and Afrique in West Africa, Humanwell Pharmaceutical Ethiopia, Xinjiang Xipa Pharmaceutical and a subsidiary in Uzbekistan; it maintains FDA-certified plants for oral solids, soft capsules and injections, with over 60 ANDA approvals, more than 500 R&D projects including 60 category 1 and 2 new drugs, 822 authorized patents and presence across Europe, the US, Japan, Russia, Australia, New Zealand, Mexico and other regions. Recent developments encompass a January 2025 restructuring investment agreement with Zhaoshang Innovation Technology Group Co., Ltd. for ¥11.8 billion, positioning it as the new controlling shareholder with a 23.70% stake through direct, indirect and trust acquisitions to resolve prior shareholder debt issues; regulatory approvals including US FDA tentative approval for a seizure treatment in September 2025, drug registration for a pain management injection in September 2025, nod for progesterone soft capsules in May 2025 and trial authorization for a pain drug in May 2025; alongside ongoing R&D in non-addictive analgesics, sustained-release microspheres, transdermal patches and anti-abuse formulations targeting anesthesia, analgesia and CNS diseases.[post:overview]